Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Seasonal Allergic Rhinitis
NCT00426179Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of imatinib in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Novartis. Primary endpoint: Reduction of mast cell degranulation (beta-tryptase and PGD2). Started Dec 2006; status: completed.
02
Drugs
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00426179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00426179.